All About Multiple Sclerosis

More MS news articles for October 2003

Perspectives in Gene Therapy for MS

Int MS J. 2003 Aug;10(3):84-8
Martino G.
Department of Neuroscience DIBIT, San Raffaele Scientific Institute, Milan, Italy.

The bloodbrain barrier limits the therapeutic efficacy of systemic administration of anti-inflammatory and/or neuroprotective molecules to patients affected by immune-mediated inflammatory demyelinating diseases of the central nervous system (CNS) such as multiple sclerosis.

Drug delivery to the CNS using non-replicative viral vectors may represent a valid alternative therapeutic strategy.

Gene therapy for multiple sclerosis might include different 'human-grade' vectors, which could be used to deliver anti-inflammatory molecules as well as neuroprotective agents into the CNS in a flexible and useful way.

These potential 'therapeutic' vectors would have different life spans, tissue tropism and infectivity rates.